The activation of the cGAS-STING pathway was also evident during liver inflammation, such as that observed in non-alcoholic fatty acid liver disease (NAFLD), hepatocellular carcinoma, cirrhosis, and viral hepatitis37. Here, CGAS is linked to metabolic dysfunction-associated steatotic liver disease.